1-Anastasiadi Z, Lianos GD, Ignatiadou E, Harissis HV, Mitsis M. Breast cancer in young women: an overview. Updates Surg. 2017;69(3):313-7.
2-Naghavi M, Marczak LB, Kutz M, Shackelford KA, Arora M, Miller-Petrie M, et al. Global Mortality From Firearms,1990-2016. Jama. 2018;320(8):792-814.
3-Jarvandi S, Montazeri A, Harirchi I, Kazemnejad A. Beliefs and behaviours of Iranian teachers toward early detection of breast cancer and breast self-examination. Public Health. 2002;116(4):245-9.
4-Asadi-Samani M, Kooti W, Aslani E, Shirzad H. A Systematic Review of Iran's Medicinal Plants With Anticancer Effects. J Evid Based Complementary Altern Med. 2016;21(2):143-53.
5-Global battle against cancer won't be won with treatment alone--effective prevention measures urgently needed to prevent cancer crisis. Cent Eur J Public Health. 2014;22(1):23, 8.
6-Monsuez JJ, Charniot JC, Vignat N, Artigou JY. Cardiac side-effects of cancer chemotherapy. Int J Cardiol. 2010;144(1):3-15.
7-Imamura T, Hikita A, Inoue Y. The roles of TGF-beta signaling in carcinogenesis and breast cancer metastasis. Breast Cancer. 2012;19(2):118-24.
8-Bierie B, Moses HL. Transforming growth factor beta (TGF-β) and inflammation in cancer. Cytokine & growth factor reviews. 2010;21(1):49-59.
9-Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61-70.
10-Venetsanakos E, Beckman I, Bradley J, Skinner JM. High incidence of interleukin 10 mRNA but not interleukin 2 mRNA detected in human breast tumours. Br J Cancer. 1826-30:(12)75;1997.
11-Changkija B, Konwar R. Role of interleukin-10 in breast cancer. Breast cancer research and treatment. 2012;133(1):11-21.
12-Yeh TC, Huang TT, Yeh TS, Chen YR, Hsu KW, Yin PH, et al. miR-151-3p Targets TWIST1 to Repress Migration of Human Breast Cancer Cells. PLoS One. 2016;11(12):e0168171.
13-Iliopoulos D, Hirsch HA, Struhl K. An epigenetic switch involving NF-κB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell. 2009;139(4):693-706.
14-Hong DS, Angelo LS, Kurzrock R. Interleukin‐6 and its receptor in cancer: implications for translational therapeutics. Cancer. 2007;110(9):1911-28.
15-Janelsins MC, Mustian KM, Palesh OG, Mohile SG, Peppone LJ, Sprod LK, et al. Differential expression of cytokines in breast cancer patients receiving different chemotherapies: implications for cognitive impairment research. Support Care Cancer. 2012;20(4):831-9.
16-Freund A, Jolivel V, Durand S, Kersual N, Chalbos D, Chavey C, et al. Mechanisms underlying differential expression of interleukin-8 in breast cancer cells. Oncogene. 2004;23(36):6105-14.
17-Kawaguchi M, Adachi M, Oda N, Kokubu F, Huang S-K. IL-17 cytokine family. Journal of Allergy and Clinical Immunology. 2004;114(6):1265-73.
18-Zarogoulidis P, Katsikogianni F, Tsiouda T, Sakkas A, Katsikogiannis N, Zarogoulidis K. Interleukin-8 and interleukin-17 for cancer. Cancer Invest. 2014;32(5):197-205.
19-Liu J, Duan Y, Cheng X, Chen X, Xie W, Long H, et al. IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma. Biochem Biophys Res Commun. 2011;407(2):348-54.
20-Sharma N, Samarakoon KW, Gyawali R, Park YH, Lee SJ, Oh SJ, et al. Evaluation of the antioxidant, anti-inflammatory, and anticancer activities of Euphorbia hirta ethanolic extract. Molecules. 2014;19(9):14567-81.
21-Kwan YP, Saito T, Ibrahim D, Al-Hassan FM, Ein Oon C, Chen Y, et al. Evaluation of the cytotoxicity, cell-cycle arrest, and apoptotic induction by Euphorbia hirta in MCF-7 breast cancer cells. Pharm Biol. 2016;54(7):1223-36.
22-Choene M, Motadi L. [Validation of the Antiproliferative Effects of Euphorbia tirucalli Extracts in Breast Cancer Cell Lines]. Mol Biol (Mosk). 2016;50(1):115-27.
23-Zare S, Ghaedi M, Miri R, Heiling S, Asadollahi M, I TB, et al. Phytochemical Investigation on Euphorbia macrostegia (Persian wood spurge). Iran J Pharm Res. 2015;14(1):243-9.